Join CustomBiotech at AMP 2024
Roche CustomBiotech at AMP 2024
Premium ingredients - the foundation of modern molecular diagnostics assays
Join Roche in Booth #901 at the AMP 2024 Annual Meeting, November 19–23, 2024, in Vancouver, Canada
Roche's broad portfolio is an optimal source of active ingredients for your diagnostic assay, from nucleic acid isolation and purification, to enzymes for amplification and nucleotides.
All ingredients are produced in accordance with ISO 13485 quality standards, and many are available in GMP Grade. Furthermore, our state-of-the-art manufacturing facilities and operating procedures ensure a continuous and worldwide supply at various scales, as well as exceptional lot-to-lot consistency. This translates to a smooth integration of ingredients into your workflows at any stage, from development to large-scale manufacturing.
Visit our booth and explore our wide range of raw materials designed for the unique requirements of centralized and point-of-care diagnostic assay development.
Join Roche Corporate Workshops
Wednesday, November 20, 2024
Optimizing Molecular Diagnostic Assay Development for RNA Targets: Enhancing Performance and Reducing Costs
9–9:50 a.m. local time
Molecular diagnostic developers face both internal and external pressures to reduce costs and improve assay performance. For example, the reverse transcription step in an RT-PCR assay drastically increases complexity encountered in molecular diagnostics. Using fast, inhibitor tolerant, and lyo-compatible reverse transcriptases can help reduce the burden on developers by enabling short overall turnaround times, streamlining or eliminating purification, and simplifying shipping and storage. Selecting the appropriate components to address the challenges in your assay can be a daunting task. At Roche CustomBiotech, we are here to assist you in finding solutions and overcoming these obstacles. Explore our wide range of reagents designed for the unique requirements of centralized and point-of-care diagnostic assay development.
